Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice

Cardiovascular Research

Volumn 101, Issue 1, 2014, Pages 87-96

  Liu, Yi ^a   Jiang, Xiao Li ^b   Liu, Yu ^c   Jiang, Ding Sheng ^a,c   Zhang, Yan ^a,c   Zhang, Rui ^a   Chen, Yingjie ^d   Yang, Qinglin ^e   Zhang, Xiao Dong ^a   Fan, Guo Chang ^f   Li, Hongliang ^a,c  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

AKT; Cardiac remodelling; Cardiomyocyte hypertrophy; Pressure overload; Tollip

Indexed keywords

ADENOVIRUS VECTOR; MEMBRANE PROTEIN; PROTEIN KINASE B; TOLL INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD PRESSURE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALADJUSTMENT; MOLECULAR INTERACTION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

AKT; CARDIAC REMODELLING; CARDIOMYOCYTE HYPERTROPHY; PRESSURE OVERLOAD; TOLLIP;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; DOWN-REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84891355711     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt232     Document Type: Article

References (32)

1. FreyN, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-1589.
2. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z et al. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci USA 2010;107:13818-13823.
3. Dickhout JG, Carlisle RE, Austin RC. Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res 2011;108:629-642.
4. Koitabashi N, Kass DA. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 2012;9:147-157.
5. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.
6. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immunedefence. Nat Rev Immunol 2007;7:179-190.
7. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G et al. Mal (myd88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001;413:78-83.
8. Kobayashi K, Hernandez LD, Galan JE, Charles A, Janeway J, MedzhitovRet al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110:191-202.
9. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized ldl. Circulation 2001;104:3103-3108.
10. Arslan F, Smeets MB, O'Neill LA, Keogh B,McGuirk P, Timmers L et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti-Toll-like receptor-2 antibody. Circulation 2010;121: 80-90.
11. Topkara VK, Evans S, ZhangW, Epelman S, Staloch L, BargerPMet al. Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol 2011;51:594-599.
12. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789.
13. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-2910.
14. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2000;2: 346-351.
15. Zhang G,Ghosh S. Negative regulation of Toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277:7059-7065.
16. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human Toll-like receptors and related genes. Biol Pharm Bull 2005;28:886-892.
17. HuY, LiT,WangY, Li J,GuoL,WuMet al. Tollip attenuated the hypertrophic response of cardiomyocytes induced by IL-1beta. Front Biosci 2009;14:2747-2756.
18. Huang H, Tang QZ,Wang AB, Chen M, Yan L, Liu C et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 2010;56:232-239.
19. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010;49:1-9.
20. Singh MV, Swaminathan PD, Luczak ED, KutschkeW,Weiss RM, Anderson ME. Myd88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol 2012;52:1135-1144.
21. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J et al. Reduced cardiac hypertrophy in Toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-234.
22. Lo YL, Beckhouse AG, Boulus SL,Wells CA. Diversification of Tollip isoforms in mouse and man. Mamm Genome 2009;20:305-314.
23. Troutman TD, HuW, Fulenchek S, Yamazaki T, Kurosaki T, Bazan JF et al. Role for B-cell adapter for PI3 K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3 K/AKT. Proc Natl Acad Sci USA 2012;109:273-278.
24. Ni M, MacFarlane AWT, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3 K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3 K. Proc Natl Acad Sci USA 2012;109:267-272.
25. Bian ZY,Wei X, Deng S, Tang QZ, Feng J, Zhang Y et al. Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) 2012;90:895-910.
26. HaT, Li Y, Gao X, McMullen JR, Shioi T, Izumo S et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radical Bio Med 2005;39: 1570-1580.
27. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M et al. Akt1 is required for physiological cardiac growth. Circulation 2006;113:2097-2104.
28. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Bio 2006;7:589-600.
29. Pandya K, Kim HS, Smithies O. Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA 2006;103:16864-16869.
30. Kang HR, Lee CG, Homer RJ, Elias JA. Semaphorin 7a plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med 2007;204:1083-1093.
31. Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M et al. Inhibition of PI3Kprevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: The role of class IP110 isoforms. PloS one 2011;6:e24663.
32. Zhu L,Wang L, Luo X, Zhang Y, Ding Q, Jiang X et al. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-beta signaling pathway. J Biol Chem 2012;287:39653-39663.